LXRX Related Analyst Ratings
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Conference Call Takeaways
-
Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Big Pipeline Undervalued
-
Lexicon Pharma (LXRX) Shares Surge as Stifel Nicolaus Adds to 'Select List,' Boosts Price Target
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); LX4211 Phase 2b Trial Data Expected Soon
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); 2012 Preview: Several Key Clinical Milestones Anticipated
-
Needham & Company 2012 Biotech Preview
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Q3 Review
-
Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Underappreciated Given Number of Phase 2 Compounds Under Development
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Encouraging Phase 2 LX1032 Results in Sandostatin-Treated Carcinoid Syndrome Patients
-
Needham & Company Starts Lexicon Pharmaceuticals (LXRX) at Buy; Valuation is Attractive
-
Wedbush Starts Lexicon Pharmaceuticals (LXRX) at Outperform; Multiple Shots on Goal Reduces Pipeline Risk
-
J.P. Morgan Initiates Coverage on Biotechnology Stocks (LXRX & IMGN)
-
Cowen & Co Initiates Coverage on Lexicon Pharmaceuticals (LXRX) with a Neutral
-
Thomas Weisel Starts Lexicon (LXRX) at Overweight, $2.50 Price Target
-
Piper Says Today's Rally in Lexicon (LXRX) is Overdone; Reiterates Underweight
-
Piper Jaffray Downgrades Lexicon Pharmaceuticals (LXRX) to Sell
-
Morgan Stanley Downgrades Lexicon Pharmaceuticals (LXRX) to Underweight
-
Piper Jaffray downgrades Lexicon Pharmaceuticals (LXRX) to Neutral
-
Banc of America Starts Lexicon Pharmaceuticals (LXRX) at Buy
Back to LXRX Stock Lookup
